Dogs are helping people regulate stress even more than expected, research shows
Assuming people's daily lives are unlikely to get less stressful anytime soon, simple and effective ways to mitigate these effects are needed.
This is where dogs can help.
As researchers at the University of Denver's Institute for Human-Animal Connection, we study the effects animal companions have on their humans.
Dozens of studies over the last 40 years have confirmed that pet dogs help humans feel more relaxed. This would explain the growing phenomenon of people relying on emotional support dogs to assist them in navigating everyday life. Dog owners have also been shown to have a 24% lower risk of death and a four times greater chance of surviving for at least a year after a heart attack.
Now, a new study that we conducted with a team of colleagues suggests that dogs might have a deeper and more biologically complex effect on humans than scientists previously believed. And this complexity may have profound implications for human health.
How stress works
The human response to stress is a finely tuned and coordinated set of various physiological pathways. Previous studies of the effects of dogs on human stress focused on just one pathway at a time. For our study, we zoomed out a bit and measured multiple biological indicators of the body's state, or biomarkers, from both of the body's major stress pathways. This allowed us to get a more complete picture of how a dog's presence affects stress in the human body.
The stress pathways we measured are the hypothalamic-pituitary-adrenal, or HPA, axis and the sympathoadrenal medullary, or SAM, axis.
When a person experiences a stressful event, the SAM axis acts quickly, triggering a 'fight or flight' response that includes a surge of adrenaline, leading to a burst of energy that helps us meet threats. This response can be measured through an enzyme called alpha-amylase.
At the same time, but a little more slowly, the HPA axis activates the adrenal glands to produce the hormone cortisol. This can help a person meet threats that might last for hours or even days. If everything goes well, when the danger ends, both axes settle down, and the body goes back to its calm state.
While stress can be an uncomfortable feeling, it has been important to human survival. Our hunter-gatherer ancestors had to respond effectively to acute stress events like an animal attack. In such instances, over-responding could be as ineffective as under-responding. Staying in an optimal stress response zone maximized humans' chances of survival.
More to the story
After cortisol is released by the adrenal glands, it eventually makes its way into your saliva, making it an easily accessible biomarker to track responses. Because of this, most research on dogs and stress has focused on salivary cortisol alone.
For example, several studies have found that people exposed to a stressful situation have a lower cortisol response if they're with a dog than if they're alone – even lower than if they're with a friend.
While these studies have shown that having a dog nearby can lower cortisol levels during a stressful event, suggesting the person is calmer, we suspected that was just part of the story.
What our study measured
For our study, we recruited about 40 dog owners to participate in a 15-minute gold standard laboratory stress test. This involves public speaking and oral math in front of a panel of expressionless people posing as behavioral specialists.
The participants were randomly assigned to bring their dogs to the lab with them or to leave their dogs at home. We measured cortisol in blood samples taken before, immediately after and about 45 minutes following the test as a biomarker of HPA axis activity. And unlike previous studies, we also measured the enzyme alpha-amylase in the same blood samples as a biomarker of the SAM axis.
As expected based on previous studies, the people who had their dog with them showed lower cortisol spikes. But we also found that people with their dog experienced a clear spike of alpha-amylase, while those without their dog showed almost no response.
No response may sound like a good thing, but in fact, a flat alpha-amylase response can be a sign of a dysregulated response to stress, often seen in people experiencing high stress responses, chronic stress or even PTSD. This lack of response is caused by chronic or overwhelming stress that can change how our nervous system responds to stressors.
In contrast, the participants with their dogs had a more balanced response: Their cortisol didn't spike too high, but their alpha-amylase still activated. This shows that they were alert and engaged throughout the test, then able to return to normal within 45 minutes. That's the sweet spot for handling stress effectively. Our research suggests that our canine companions keep us in a healthy zone of stress response.
Dogs and human health
This more nuanced understanding of the biological effects of dogs on the human stress response opens up exciting possibilities. Based on the results of our study, our team has begun a new study using thousands of biomarkers to delve deeper into the biology of how psychiatric service dogs reduce PTSD in military veterans.
But one thing is already clear: Dogs aren't just good company. They might just be one of the most accessible and effective tools for staying healthy in a stressful world.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Kevin Morris, University of Denver and Jaci Gandenberger, University of Denver
Read more:
Service dogs can help veterans with PTSD – growing evidence shows they may reduce anxiety in practical ways
Lending a helping paw: Dogs will aid their crying human
Therapy dogs help students cope with the stress of college life
Kevin Morris receives funding for this research from the Morris Animal Foundation, the Human-Animal Bond Research Institute, and the University of Denver.
Jaci Gandenberger receives funding from the University of Denver to support this research.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
23 minutes ago
- Yahoo
Sarepta falls after gene therapy maker pauses Elevidys shipments in US
(Reuters) -Shares of Sarepta Therapeutics fell nearly 7% on Tuesday after the company agreed to comply with the U.S. health regulator's request to pause all shipments of its gene therapy Elevidys in the United States. The U.S. Food and Drug Administration on Friday asked Sarepta to voluntarily halt shipments of the gene therapy, but the company refused to do so and said it would continue making the treatment available to ambulatory patients. But Sarepta has now voluntarily and temporarily paused all shipments of the therapy, effective end of Tuesday. The company said the decision would allow it to respond to requests from the FDA and maintain a positive relationship with the agency. "Though Sarepta claims its pause in shipments was voluntary, we think the company moved preemptively — bracing for an inevitable FDA mandate to pull the drug," said H.C. Wainwright analyst Mitchell Kapoor. Shares of Sarepta fell 6.9% to $12.40 in early trading on Tuesday. "Sarepta's decision to comply was a capitulation after recognizing that the fight with the FDA was not winnable and that the agency would have strong-armed Sarepta into removing Elevidys with a formal demand," Kapoor added. Investor concerns regarding the use of the company's treatments have been heightened after the company on Friday disclosed that another patient who had received its experimental gene therapy died from acute liver failure, marking the third death this year. The company's shares have plummeted 89% so far this year. On Monday, Children's Hospital Los Angeles said it had paused usage of Elevidys in all patients with muscular dystrophy. The FDA's initial request had likely heightened the pressure on physicians to pause treatments, which could also have been a driving factor in Sarepta's decision, William Blair analyst Sami Corwin said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
HealthStream to Host Second Quarter 2025 Earnings Conference Call
NASHVILLE, Tenn., July 22, 2025--(BUSINESS WIRE)--HealthStream, Inc. (Nasdaq: HSTM), a leading healthcare technology platform company for workforce solutions, announced today that it will host a conference call and webcast to discuss its second quarter 2025 financial results on Tuesday, August 5, 2025. The Company's financial results for the second quarter 2025 ended June 30, 2025 will be released after the routine time for the close of the market on Monday, August 4, 2025. HealthStream's second quarter 2025 earnings conference call will begin at 9:00 a.m. Eastern Time on Tuesday, August 5, 2025. Participants may access the conference call live via webcast using this LINK. To participate via telephone, please register in advance using this LINK. Upon registration, all telephone participants will receive a one-time confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. All participants are instructed to dial-in 15 minutes prior to the start time. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. About HealthStream HealthStream (Nasdaq: HSTM) is the healthcare industry's largest ecosystem of platform-delivered workforce solutions that empowers healthcare professionals to do what they do best: deliver excellence in patient care. For more information, visit or call 615-301-3100. This press release contains forward-looking statements that involve risks and uncertainties regarding HealthStream. This information has been included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such results or events predicted in these statements may differ materially from actual future events or results. These forward-looking statements are based on a variety of assumptions that may not be realized, and which are subject to significant risks and uncertainties, including that the anticipated financial and strategic benefits of the acquisition may not be realized, as well as risks and uncertainties referenced from time to time in the Company's filings with the Securities and Exchange Commission. View source version on Contacts Mollie Condra, Investor Relations &CommunicationsHealthStream(615)-


Fast Company
25 minutes ago
- Fast Company
AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy. The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement. It will also upgrade the Anglo-Swedish drugmaker's U.S. clinical trial supply network and support ongoing investment in novel medicines. On Monday, AstraZeneca said the expansion supports its ambition to reach $80 billion in annual revenue by 2030, with half coming from the U.S. The U.S. accounted for more than 40% of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market — the world's largest, worth $635 billion — before Trump's return to office. The move to scale up its U.S. footprint is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes. Trump has called on pharma companies to make more of the medicines they sell in the U.S. within the country, rather than importing active ingredients or finished medicines. He is also pushing for prices in the U.S. to fall to what other countries pay. CEO Pascal Soriot announced the plans in Washington, saying he believes that drug prices need to rise elsewhere and 'equalize' with other countries effectively contributing more to research and development costs. 'The United States cannot build or carry the cost of R&D for the entire world,' he said. U.S. Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs. 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness,' said Lutnick in a statement issued by AstraZeneca. While Trump has repeatedly threatened tariffs on the sector, he signalled earlier this month that companies would be given a year to 18 months to 'get their act together' before any levies take effect. The company said that the timing and location of the announcement was linked to the U.S. policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place. The pledge is in addition to the $3.5 billion in investments the company announced in November 2024, the statement said. PLEDGES The $50 billion pledge matches the commitment announced by Swiss rival Roche in April and follows new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson, Novartis, and Sanofi. Also present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies. The new Virginia facility — the company's largest single manufacturing investment — will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said. The company said the investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the U.S. and has a global workforce of about 90,000. In January it scrapped plans to invest 450 million pounds ($607.1 million) in its vaccine manufacturing plant in northern England, citing a cut in government support. Earlier this month, The Times reported the company was considering moving its stock market listing from London, where it is the exchange's most valuable company worth 159 billion pounds, to the U.S. The company declined to comment.